| IBD treatment prior to baseline | All patients (IBD) | Crohn’s disease | Ulcerative colitis |
|--------------------------------|-------------------|-----------------|-------------------|
| **Conventional oral treatment, n (%)** |                   |                 |                   |
| 5-aminosalisylic acid             | 61 (68.5)         | 24 (50)         | 37 (90.2)         |
| Azathioprine                       | 76 (85.4)         | 42 (87.5)       | 34 (82.9)         |
| 6-mercaptopurine                   | 14 (15.7)         | 8 (16.7)        | 6 (14.6)          |
| Methotrexate                       | 24 (27.0)         | 18 (37.5)       | 6 (14.6)          |
| Systemic corticosteroids<sup>a</sup> | 70 (78.7)         | 34 (70.8)       | 36 (87.8)         |
| Budesonide                         | 39 (43.8)         | 27 (56.3)       | 12 (29.3)         |
| **Topical treatment, n (%)**       |                   |                 |                   |
| 5-aminosalisylic acid              | 36 (40.4)         | 6 (12.5)        | 30 (73.2)         |
| Corticosteroids<sup>b</sup>        | 30 (33.7)         | 9 (18.8)        | 21 (51.2)         |
| **Prior biologic or Ianus Kinase inhibitor treatment, n (%)** |                   |                 |                   |
| Vedolizumab (IV)                   | 89 (100)          | 48 (100)        | 41 (100)          |
| Infliximab                         | 70 (78.7)         | 38 (79.2)       | 32 (78)           |
| Adalimumab                         | 47 (52.8)         | 34 (70.8)       | 13 (31.7)         |
| Ustekinumab                        | 2 (2.2)           | 2 (4.2)         | 0 (0.0)           |
| Golimumab                          | 1 (1.1)           | 1 (2.1)         | 0 (0.0)           |
| Certolizumab                       | 1 (1.1)           | 1 (2.1)         | 0 (0.0)           |
| Natalizumab                        | 1 (1.1)           | 1 (2.1)         | 0 (0.0)           |
| Tofacitinib                        | 3 (3.4)           | 0 (0.0)         | 3 (7.5)           |
| **Changes in treatment during primary study period, n (%)** |                   |                 |                   |
| Vedolizumab dose optimized (to 108 mg once weekly) | 9 (10.1)         | 6 (12.5)        | 3 (7.5)           |
| Vedolizumab discontinued           | 4 (4.5)           | 0 (0.0)         | 4 (9.8)           |
| Added                              |                   |                 |                   |
| None                               | 83 (93.3)         | 44 (91.7)       | 39 (95.1)         |
| Systemic corticosteroids<sup>a</sup> | 3 (3.4)           | 2 (4.2)         | 1 (2.4)           |
| Oral budesonide                    | 1 (1.1)           | 1 (2.1)         | 0 (0.0)           |
| Topical corticosteroids<sup>b</sup> | 3 (3.4)           | 2 (4.2)         | 1 (2.4)           |
| Antibiotics                        | 1 (1.1)           | 1 (2.1)         | 0 (0.0)           |
| Discontinued                       |                   |                 |                   |
| None                               | 84 (94.4)         | 47 (97.9)       | 37 (41)           |
| Oral 5-aminosalisylic acid         | 3 (3.4)           | 1 (2.1)         | 2 (4.9)           |
| Azathioprine                       | 1 (1.1)           | 0 (0.0)         | 1 (2.4)           |
| Oral prednisolone                  | 1 (1.1)           | 0 (0.0)         | 1 (2.4)           |
| Dose increased                     |                   |                 |                   |
| Oral 5-aminosalisylic acid         | 1 (1.1)           | 0 (0.0)         | 1 (2.4)           |

<sup>a</sup>Prednisolone or betamethasone (oral or iv), <sup>b</sup>prednisolone or budesonide.

Abbreviations: IBD, inflammatory bowel disease; IV, intravenous; n, number of patients.